4.6 Article

Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems

Journal

CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 96, Issue 4, Pages 482-489

Publisher

WILEY-BLACKWELL
DOI: 10.1038/clpt.2014.137

Keywords

-

Funding

  1. Cincinnati Children's Hospital Medical Center/Harvard [U01HG006828]
  2. Children's Hospital of Philadelphia [U01HG006830]
  3. Essentia Institute of Rural Health [U01HG006389]
  4. Geisinger Clinic [U01HG006382]
  5. Group Health Cooperative [U01HG006375]
  6. University of Washington [U01HG006375]
  7. Mayo Clinic [U01HG006379]
  8. Icahn School of Medicine at Mount Sinai [U01HG006380]
  9. Northwestern University [U01HG006388]
  10. Vanderbilt University [U01HG006378]
  11. Vanderbilt serving as the coordinating center [U01HG006385]
  12. Deep Resequencing Resources of the Pharmacogenomic Research Network [U01 HL069757, U19 GM61388, U01 GM097119]
  13. National Human Genome Research Institute [5U01HG006507]
  14. Mayo Clinic Center for Individualized Medicine
  15. National Institutes of Health (Pharmacogenomics Research Network) [U19 GM61388]
  16. Rochester Epidemiology Project [R01 GM28157, U01 HG005137, R01 CA138461, R01 AG034676]
  17. Pharmacogenomics of Arrhythmia Therapy PGRN site grant from the National Institute of General Medical Sciences
  18. National Heart, Lung, and Blood Institute [U19 HL65262]
  19. [U01HG004438]
  20. [HL069757]

Ask authors/readers for more resources

We describe here the design and initial implementation of the eMERGE-PGx project. eMERGE-PGx, a partnership of the Electronic Medical Records and Genomics Network and the Pharmacogenomics Research Network, has three objectives: (i) to deploy PGRNseq, a next-generation sequencing platform assessing sequence variation in 84 proposed pharmacogenes, in nearly 9,000 patients likely to be prescribed drugs of interest in a 1- to 3-year time frame across several clinical sites; (ii) to integrate well-established clinically validated pharmacogenetic genotypes into the electronic health record with associated clinical decision support and to assess process and clinical outcomes of implementation; and (iii) to develop a repository of pharmacogenetic variants of unknown significance linked to a repository of electronic health record-based clinical phenotype data for ongoing pharmacogenomics discovery. We describe site-specific project implementation and anticipated products, including genetic variant and phenotype data repositories, novel variant association studies, clinical decision support modules, clinical and process outcomes, approaches to managing incidental findings, and patient and clinician education methods.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available